McMillan Office’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
McMillan Office's BMY Position: Q2 2026 in Review
McMillan Office reduced its Bristol-Myers Squibb (BMY) stake by 1.2% in Q2 2026, selling an estimated $57.4K and leaving 79,193 shares worth $4.56M. The position accounts for 0.52% of the portfolio, ranked #28.
McMillan Office first reported a position in BMY in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.86M in Q1 2026. 2,508 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- McMillan Office held 79,193 shares of Bristol-Myers Squibb worth $4.56M as of Q2 2026.
- McMillan Office sold 1,000 Bristol-Myers Squibb shares in Q2 2026, an estimated $57.4K.
- Bristol-Myers Squibb made up 0.52% of McMillan Office's portfolio in Q2 2026, its #28 holding.
- McMillan Office first reported a position in Bristol-Myers Squibb in Q4 2025 and has held it in 3 quarters since.
- McMillan Office's Bristol-Myers Squibb position peaked at $4.86M in Q1 2026.
- 2,508 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on McMillan Office's 13F filing for Q2 2026, filed 13 Aug 2026.